PharVision Advisers’s AMERISAFE AMSF Stock Holding History

PharVision Advisers’s Portfolio AMSF Stock Details AMSF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,760	Closed	-$336K	–	123
2025 Q4	$336K	Buy	8,760 +3,683	+73%	+$149K	0.17%	219
2025 Q3	$223K	Buy	+5,077	New	+$228K	0.13%	416

Other funds holding AMSF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PharVision Advisers's AMSF Position: Q1 2026 in Review

PharVision Advisers sold out of AMERISAFE (AMSF) in Q1 2026, closing a stake of 8,760 shares — an estimated $336K sold.

PharVision Advisers first reported a position in AMSF in Q3 2025 and held it in 2 quarters. The position peaked at $336K in Q4 2025. 182 funds tracked by Wall St. Rank hold AMSF as of Q1 2026.

PharVision Advisers reported no remaining AMERISAFE position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 8,760 AMERISAFE shares in Q1 2026, an estimated $336K.
PharVision Advisers first reported a position in AMERISAFE in Q3 2025 and held it in 2 quarters.
PharVision Advisers's AMERISAFE position peaked at $336K in Q4 2025.
182 funds tracked by Wall St. Rank held AMERISAFE as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.